spacer
home > ict > winter 2008 > we can be heroes
PUBLICATIONS
International Clinical Trials

We Can be Heroes

Describing the public health benefits of promoting patient participation, Kenneth Getz at the Tufts Center for the Study of Drug Development, James Kremidas at Eli Lilly and Company, Elizabeth Carfioli of Ogilvy Healthworld Consulting (US) and Rachael Butlin at Fast4wD Ogilvy (UK) challenge public perceptions of clinical trials

A GLOBAL PROBLEM

Clinical research is essential for developing treatments that improve public health. Without it, many medical advances that ease human suffering, offer better treatment options and even cure life-threatening illnesses would never have been introduced.

Despite the high importance of clinical research and the access to investigational new treatments that it affords, patient participation rates are low. As few as 10 per cent of eligible patients in the US participate in clinical trials (1) – a figure that is only slightly higher than other parts of the world, which sit at an overall participation rate of only six to eight per cent of eligible patients (2). Pharmaceutical companies are increasingly investing in communication programmes to ensure awareness and knowledge of the studies that they are conducting and, ultimately, to increase patient participation in clinical trials.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Kenneth A Getz is the chairman of CISCRP – a non-profit organisation that he founded to educate and raise public awareness of the clinical research enterprise – and a Senior Research fellow at the Tufts Center for the Study of Drug Development, where he studies R&D management and operating models, investigative sites, outsourcing and study volunteer trends and policies. A wellknown speaker, Ken has published over 150 articles and two books, and serves on a number of corporate and non-profit boards. Ken is also the founder and former CEO of CenterWatch, a leading publisher in the clinical trials industry.

Jim Kremidas leads the clinical trial patient recruitment and retention efforts at Eli Lilly and Company. His role focuses on predicting and accelerating the enrolment rates for all corporate studies. Jim is a member of the Steering Committee for the Center for Information and Study on Clinical Research Participation (CISCRP).

Elizabeth Carfioli has over 10 years of experience in the strategic planning and implementation of global patient recruitment and retention programmes, having worked for both agencies and sponsors. She is currently working for Ogilvy Healthworld Consulting, providing strategic counsel to clients on improving internal processes for enrolment acceleration.

Rachael Butlin is an Account Manager at Fast4wD Ogilvy, a specialised global patient recruitment and retention company. She has a business and marketing background, and has combined this experience with her knowledge of study stakeholder needs in outlining bespoke global programmes for a number of top pharmaceutical study sponsors. Her expertise spans numerous therapy areas including pain, oncology and mental health.

spacer
Kenneth A Getz
spacer
spacer
spacer
Jim Kremidas
spacer
spacer
spacer
Elizabeth Carfioli
spacer
spacer
spacer
Rachael Butlin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Significant improvement in overall survival with ERLEADA®▼ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer

BEERSE, BELGIUM, May 14, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the final analysis of the pivotal Phase 3 SPARTAN study demonstrating ERLEADA®▼ (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved overall survival (OS), compared to ADT alone, in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.1 Results will be presented at the American Society of Clinical Oncology (ASCO) Virtual Scientific Programme (Abstract #5516) beginning on Friday 29th May.
More info >>

White Papers

Digital Transformation of the Cold Chain

Sensitech EMEA

The Life Sciences cold chain is a seamless and interconnected global network of people, equipment, data and processes that helps to ensure the safety and integrity of our medicines and vaccines. Cold chain logistics spending totaled $13 billion in 2017, an investment designed to protect some $283 billion in Life Sciences cold chain products, growing at 19% annually.1 Sensitech Inc., a part of UTC Climate, Controls & Security, a unit of United Technology Corp., has played an essential part in the Life Sciences cold chain since 1990, providing a comprehensive set of solutions for manufacturers of biologics, prescription pharmaceuticals, clinical trial materials, and over-the-counter drugs. These solutions help to ensure product quality, patient safety, and regulatory compliance while helping to prevent theft and optimizing cold chain performance.
More info >>

 
Industry Events

Outsourcing in Clinical Trials Europe

26-27 October 2020, Paris, France

Arena International are delighted to announce the return of Outsourcing in Clinical Trials Europe. Part of our global series of events, this flagship show will attract the leading clinical professionals from across Europe. The 10th Annual event will be hosted in Paris.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement